New antibiotic YK-1169 takes on deadly hospital pneumonia
NCT ID NCT07634198
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a new antibiotic called YK-1169 against a standard treatment (ceftazidime-avibactam) for adults with pneumonia caught in the hospital or from a ventilator. About 590 participants will receive either drug for 7-14 days. The main goal is to see if YK-1169 lowers the chance of death within 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- YK-1169 (an experimental antibiotic)
- What this could lead to
- If successful, YK-1169 could offer a new treatment option for serious hospital-acquired pneumonia, potentially reducing deaths.
- What could go wrong
- This is an early Phase 3 trial, so results may not confirm superiority or safety. The drug could cause side effects or fail to improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.